2023
Identification of blood protein biomarkers associated with prostate cancer risk using genetic prediction models: analysis of over 140,000 subjects
Zhong H, Zhu J, Liu S, Ghoneim D, Surendran P, Liu T, Fahle S, Butterworth A, Alam A, Deng H, Yu H, Wu C, Wu L. Identification of blood protein biomarkers associated with prostate cancer risk using genetic prediction models: analysis of over 140,000 subjects. Human Molecular Genetics 2023, 32: 3181-3193. PMID: 37622920, PMCID: PMC10630250, DOI: 10.1093/hmg/ddad139.Peer-Reviewed Original ResearchConceptsPCa riskProstate cancerHuge public health burdenEtiology of PCaBlood protein biomarkersConventional epidemiologic studiesProstate cancer riskPublic health burdenConventional observational studiesCancer Genome AtlasPCa patientsHealth burdenProtein biomarker candidatesObservational studyEpidemiologic studiesCancer riskTherapeutic strategiesCancer-related pathwaysSignificant associationBiomarker candidatesGenome AtlasProtein levelsDrug repurposingRiskPositive associationAssociation between use of antihypertensive drugs and the risk of cancer: a population-based cohort study in Shanghai
Wang S, Xie L, Zhuang J, Qian Y, Zhang G, Quan X, Li L, Yu H, Zhang W, Zhao W, Qian B. Association between use of antihypertensive drugs and the risk of cancer: a population-based cohort study in Shanghai. BMC Cancer 2023, 23: 425. PMID: 37165412, PMCID: PMC10173582, DOI: 10.1186/s12885-023-10849-8.Peer-Reviewed Original ResearchConceptsPopulation-based cohort studyTotal cancerAntihypertensive drugsHypertensive patientsCohort studyAntihypertensive medicinesThyroid cancerHigh riskPossible dose-response relationshipAntihypertensive drug administrationCommon antihypertensive drugsRisk of cancerCommunity healthcare centersDose-response relationshipMajor cancer typesAntihypertensive classesCancer casesMAIN OUTCOMECancer riskHealthcare centersDrug AdministrationPatientsSignificant associationCancerCancer types
2012
Meta-Analysis of the Association between Mir-196a-2 Polymorphism and Cancer Susceptibility
Zhang H, Su Y, Yu H, Qian B. Meta-Analysis of the Association between Mir-196a-2 Polymorphism and Cancer Susceptibility. Cancer Biology & Medicine 2012, 9: 63-72. PMID: 23691458, PMCID: PMC3643645, DOI: 10.3969/j.issn.2095-3941.2012.01.012.Peer-Reviewed Original ResearchColorectal cancerSubgroup analysisCancer riskCancer susceptibilityMiR-196aRs11614913 polymorphismRisk of lungCase-control studyIndependent case-control studiesRisk of cancerDifferent tumor typesMiR-196a-2Esophageal cancerLung cancerBreast cancerTumor typesCaucasian subgroupMeta-AnalysisSignificant associationC alleleOverall associationCancerGenetic modelsAsian populationsMicroRNA dysregulation
1996
Ultrasensitive detection of prostate-specific antigen by a time-resolved immunofluorometric assay and the Immulite immunochemiluminescent third-generation assay: potential applications in prostate and breast cancers.
Ferguson R, Yu H, Kalyvas M, Zammit S, Diamandis E. Ultrasensitive detection of prostate-specific antigen by a time-resolved immunofluorometric assay and the Immulite immunochemiluminescent third-generation assay: potential applications in prostate and breast cancers. Clinical Chemistry 1996, 42: 675-684. PMID: 8653891, DOI: 10.1093/clinchem/42.5.675.Peer-Reviewed Original ResearchConceptsTime-resolved immunofluorometric assayProstate-specific antigenL PSAPotential applicationsUltrasensitive time-resolved immunofluorometric assayUltrasensitive detectionPSA immunoreactivityImmunofluorometric assayWide dynamic rangeFree prostate-specific antigenPostradical prostatectomy patientsEstrogen receptor positivityUltrasensitive PSA assaysDynamic rangePSA changeReceptor positivityProstatectomy patientsProstate cancerBreast cancerPSA assaysHook effectLow analytical limitsSignificant associationMonoclonal antibodiesSerum samples